

Janet B McGill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5376698/publications.pdf>

Version: 2024-02-01

54
papers

3,404
citations

279487

23
h-index

182168

51
g-index

54
all docs

54
docs citations

54
times ranked

3558
citing authors

#	ARTICLE	IF	CITATIONS
1	Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 894-903.	0.4	48
2	Insulin Receptor Autoantibody-mediated Hypoglycemia in a Woman With Mixed Connective Tissue Disease. <i>Journal of the Endocrine Society</i> , 2022, 6, bvab182.	0.1	2
3	Real-World Evidence Supporting Tandem Control-IQ Hybrid Closed-Loop Success in the Medicare and Medicaid Type 1 and Type 2 Diabetes Populations. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 814-823.	2.4	22
4	Monogenic and syndromic diabetes due to endoplasmic reticulum stress. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107618.	1.2	18
5	Understanding inhaled Technosphere Insulin: Results of an early randomized trial in type 1 diabetes mellitus. <i>Journal of Diabetes</i> , 2021, 13, 164-172.	0.8	8
6	Letter to the Editor from McKee and McGill: "Glycemic Control and Variability of Diabetes Secondary to Total Pancreatectomy Assessed by Continuous Glucose Monitoring". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4298-e4299.	1.8	0
7	Lost in Translation: A Disconnect Between the Science and Medicare Coverage Criteria for Continuous Subcutaneous Insulin Infusion. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 715-725.	2.4	7
8	Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 2262.	3.8	182
9	What's Wrong with This Picture? A Critical Review of Current Centers for Medicare & Medicaid Services Coverage Criteria for Continuous Glucose Monitoring. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 652-660.	2.4	26
10	The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. <i>Diabetes Care</i> , 2021, 44, 2729-2737.	4.3	24
11	Update on Biosimilar Insulins: A US Perspective. <i>BioDrugs</i> , 2020, 34, 505-512.	2.2	6
12	Comprehensive Pulmonary Safety Review of Inhaled Technosphere® Insulin in Patients with Diabetes Mellitus. <i>Clinical Drug Investigation</i> , 2020, 40, 973-983.	1.1	7
13	Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 2397.	3.8	191
14	Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2020, 382, 2493-2503.	13.9	228
15	Evidence-based treatment of hyperglycaemia with incretin therapies in patients with type 2 diabetes and advanced chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1014-1023.	2.2	5
16	Low dose chloroquine decreases insulin resistance in human metabolic syndrome but does not reduce carotid intima-media thickness. <i>Diabetology and Metabolic Syndrome</i> , 2019, 11, 61.	1.2	15
17	Biologic and social factors predict incident kidney disease in type 1 diabetes: Results from the T1D exchange clinic network. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 107400.	1.2	4
18	Optimizing Postprandial Glucose Management in Adults With Insulin-Requiring Diabetes: Report and Recommendations. <i>Journal of the Endocrine Society</i> , 2019, 3, 1942-1957.	0.1	16

#	ARTICLE	IF	CITATIONS
19	Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. American Journal of Medicine, 2019, 132, S49-S57.e5.	0.6	11
20	Culinary Medicine: Advancing a Framework for Healthier Eating to Improve Chronic Disease Management and Prevention. Clinical Therapeutics, 2019, 41, 2184-2198.	1.1	30
21	Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism, 2019, 21, 1199-1208.	2.2	83
22	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinolâ€”Rationale, Design, and Baseline Data. Diabetes Care, 2019, 42, 1454-1463.	4.3	39
23	Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. American Journal of Cardiology, 2019, 124, S45-S52.	0.7	62
24	Visual Field Loss in Patients With Diabetes in the Absence of Clinically-Detectable Vascular Retinopathy in a Nationally Representative Survey. , 2019, 60, 4711.		14
25	High prevalence of comorbid autoimmune diseases in adults with type 1 diabetes from the HealthFacts database. Journal of Diabetes, 2019, 11, 273-279.	0.8	29
26	Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 2019, 73, 309-315.	2.1	18
27	Mistaken Identity: Missed Diagnosis of Type 1 Diabetes in an Older Adult. Medical Research Archives, 2019, 7, .	0.1	2
28	Effect of a Shoulder Movement Intervention on Joint Mobility, Pain, and Disability in People With Diabetes: A Randomized Controlled Trial. Physical Therapy, 2018, 98, 745-753.	1.1	11
29	High prevalence of systemic rheumatic diseases in women with type 1 diabetes. Journal of Diabetes and Its Complications, 2018, 32, 737-739.	1.2	4
30	Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections. JAMA - Journal of the American Medical Association, 2017, 317, 371.	3.8	834
31	ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. American Journal of Kidney Diseases, 2017, 70, 522-531.	2.1	15
32	Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections. Annals of Internal Medicine, 2017, 167, 365.	2.0	385
33	Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial. Lancet Diabetes and Endocrinology, the, 2017, 5, 700-708.	5.5	99
34	Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.1	13
35	Moyamoya syndrome causing stroke in young women with type 1 diabetes. Journal of Diabetes and Its Complications, 2016, 30, 1640-1642.	1.2	10
36	Diabetic Kidney Disease. Missouri Medicine, 2016, 113, 390-394.	0.3	9

#	ARTICLE	IF	CITATIONS
37	Type 2 diabetes, obesity, and sex difference affect the fate of glucose in the human heart. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2015, 308, H1510-H1516.	1.5	31
38	Relationship Between Skin Intrinsic Fluorescence and an Indicator of Advanced Glycation End Products and Upper Extremity Impairments in Individuals With Diabetes Mellitus. <i>Physical Therapy</i> , 2015, 95, 1111-1119.	1.1	19
39	Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naïve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents. <i>Diabetes Care</i> , 2015, 38, 2274-2281.	4.3	30
40	Safety and Efficacy of Hyperglycemia Urgency Order Set. <i>Journal of Diabetes Science and Technology</i> , 2014, 8, 1062-1063.	1.3	0
41	Anti-Diabetes Therapy: Safety Considerations for Patients With Impaired Kidney Function. <i>Postgraduate Medicine</i> , 2014, 126, 161-171.	0.9	2
42	Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. <i>BMJ Open Diabetes Research and Care</i> , 2014, 2, e000011.	1.2	31
43	The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review. <i>Diabetes Therapy</i> , 2014, 5, 43-63.	1.2	40
44	Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment. <i>Diabetes Care</i> , 2013, 36, 237-244.	4.3	162
45	Pharmacotherapy in Type 2 Diabetes: A Functional Schema for Drug Classification. <i>Current Diabetes Reviews</i> , 2012, 8, 257-267.	0.6	18
46	Potential of abnormalities in myocardial metabolism with the development of diabetes in women with obesity and insulin resistance. <i>Journal of Nuclear Cardiology</i> , 2011, 18, 421-429.	1.4	38
47	Impact of Incretin Therapy on Islet Dysfunction: An Underlying Defect in the Pathophysiology of Type 2 Diabetes. <i>Postgraduate Medicine</i> , 2009, 121, 46-58.	0.9	15
48	Progress and Controversies: Treating Obesity and Insulin Resistance in the Context of Hypertension. <i>Journal of Clinical Hypertension</i> , 2009, 11, 36-41.	1.0	22
49	Selecting among ADA/EASD tier 1 and tier 2 treatment options. <i>Journal of Family Practice</i> , 2009, 58, S26-34.	0.2	1
50	Clinical safety of the selective PKC- β inhibitor, ruboxistaurin. <i>Expert Opinion on Drug Safety</i> , 2006, 5, 835-845.	1.0	42
51	Anemia and the role of erythropoietin in diabetes. <i>Journal of Diabetes and Its Complications</i> , 2006, 20, 262-272.	1.2	69
52	Circulating 1,5-Anhydroglucitol Levels in Adult Patients With Diabetes Reflect Longitudinal Changes of Glycemia: A U.S. trial of the GlycoMark assay. <i>Diabetes Care</i> , 2004, 27, 1859-1865.	4.3	126
53	Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Therapy Are Equally Effective in Type 2 Diabetes: A randomized, parallel-group, 24-week study. <i>Diabetes Care</i> , 2003, 26, 2598-2603.	4.3	235
54	Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. <i>Clinical Cardiology</i> , 2001, 24, 66-72.	0.7	46